Pharmacogenomics and epigenomics of age-related neurodegenerative disorders: strategies for drug development
| dc.contributor.author | Cacabelos, Ramón | |
| dc.contributor.author | Carril, Juan Carlos | |
| dc.contributor.author | Teijido Hermida, Óscar | |
| dc.contributor.department | Ciencias de la Salud | es_ES |
| dc.contributor.department | Osasun Zientziak | eu |
| dc.date.accessioned | 2025-04-01T10:19:25Z | |
| dc.date.available | 2025-04-01T10:19:25Z | |
| dc.date.issued | 2017 | |
| dc.date.updated | 2025-04-01T10:14:37Z | |
| dc.description | Acceso cerrado a este documento. No se encuentra disponible para la consulta pública. Depositado en Academica-e para cumplir con los requisitos de evaluación y acreditación académica del autor/a (sexenios, acreditaciones, etc.). | |
| dc.format.mimetype | application/pdf | en |
| dc.identifier.citation | Cacabelos, R., Carril, J. C., Teijido, O. (2017). Pharmacogenomics and epigenomics of age-related neurodegenerative disorders: strategies for drug development. In Vaiserman A. M. (Ed.), Anti-aging drugs: from basic research to clinical practice (pp. 75-141). Royal Society of Chemistry. https://doi.org/10.1039/9781782626602-00075. | |
| dc.identifier.doi | 10.1039/9781782626602-00075 | |
| dc.identifier.isbn | 978-1-78262-435-6 | |
| dc.identifier.uri | https://academica-e.unavarra.es/handle/2454/53878 | |
| dc.language.iso | eng | |
| dc.publisher | Royal Society of Chemistry | |
| dc.relation.publisherversion | https://doi.org/10.1039/9781782626602-00075 | |
| dc.rights.accessRights | info:eu-repo/semantics/closedAccess | |
| dc.title | Pharmacogenomics and epigenomics of age-related neurodegenerative disorders: strategies for drug development | en |
| dc.type | info:eu-repo/semantics/bookPart | |
| dspace.entity.type | Publication | |
| relation.isAuthorOfPublication | 2af87636-fad2-48e3-b5f6-f4a704d93613 | |
| relation.isAuthorOfPublication.latestForDiscovery | 2af87636-fad2-48e3-b5f6-f4a704d93613 |